Fine Vine: Old Dog,...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$4.55 0.00 | 0.00%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 47.45M | 289.64M | 185.04M | 151.76M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | -12.60M |
| Gross Operating Profit | 47.45M | 289.64M | 185.04M | 164.35M |
| Selling, General, and Administrative Expenses | 31.84M | 33.13M | 33.02M | 38.96M |
| Research & Development | 128.88M | 156.84M | 210.68M | 234.70M |
| Operating Income before D & A (EBITDA) | -113.26M | 99.67M | -58.65M | -109.31M |
| Depreciation & Amortization | 20.47M | 6.82M | 10.54M | 12.60M |
| Interest Income | 1.99M | 1.46M | 138.00K | 1.51M |
| Other Income - Net | 0.00 | 2.25M | 8.20M | -7.77M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -140.92M | 86.43M | -93.60M | -128.17M |
| Interest Expense | 27.09M | 16.26M | 9.34M | 12.67M |
| Pre-Tax Income | -168.01M | 70.17M | -102.94M | -140.84M |
| Income Taxes | 107.00K | 1.30M | -72.00K | -1.29M |
| Minority Interest | 0.00 | 0.00 | 0.00 | -4.34M |
| Net Income From Continuing Operations | -147.64M | 75.70M | -92.33M | -135.22M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -147.64M | 75.70M | -92.33M | -135.22M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -147.64M | 75.70M | -92.33M | -135.22M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-138.47M | 85.83M | -59.59M | -135.22M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -147.64M | 75.70M | -92.33M | -135.22M |
| Basic EPS from Continuing Ops. | -0.92 | 0.60 | -0.85 | -1.26 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.92 | 0.60 | -0.85 | -1.26 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.92 | 0.60 | -0.85 | -1.26 |
| Basic Normalized Net Income/Share | -0.86 | 0.68 | -0.55 | -1.26 |
| EPS fr Continuing Ops. | -0.92 | 0.58 | -0.85 | -1.26 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.92 | 0.58 | -0.85 | -1.26 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.92 | 0.58 | -0.85 | -1.26 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.86 | 0.66 | -0.55 | -1.26 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with EXEL
- Portfolio NameUser Type
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Under-$10 Setting Up...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Stocks That Could Rise i...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
Latest EXEL Headlines from TheStreet
- EXEL Crosses Above Key Moving Average Level 05.08.13 | 04:05 pm
- 'Mad Money' Lightning Round: Buy, Buy, Buy Toll Brothers 04.17.13 | 06:04 am
- Exelixis Inc. Stock Downgraded (EXEL) 02.27.13 | 04:02 am
- Arena Pharmaceuticals And 6 More Stocks To Watch 01.07.13 | 07:01 pm
- Shorting Alexza Pharma On FDA's Adasuve Approval 12.19.12 | 07:12 am
- Exelixis Scores FDA Approval For Thyroid Cancer Drug 11.29.12 | 04:11 pm
- 'Mad Money' Lightning Round: Buy Philips 66 and Sprint 11.27.12 | 06:11 am
- Cramer's 'Mad Money' Recap: A Tale of Two Markets 11.26.12 | 07:11 pm
- Exelixis Preps For Thyroid Cancer Drug Approval 11.26.12 | 10:11 am
- Cramer's 'Mad Money' Recap: Good Reasons to Stay in the Market 11.13.12 | 07:11 pm
Press Releases for EXEL
- Exelixis Announces Webcast Of March 4 Presentation At The 33rd Annual Cowen Health Care Conference - Business Wire 02.25.13 | 04:02 pm
- Exelixis Selects Swedish Orphan Biovitrum AB As COMETRIQ™ European Distributor For Medullary Thyroid Cancer - Business Wire 02.21.13 | 04:02 pm
- Exelixis Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.21.13 | 04:02 pm
- Exelixis Announces February 21st Webcast Of Fourth Quarter And Full Year 2012 Financial Results Conference Call - Business Wire 02.07.13 | 04:02 pm
- Exelixis Announces Webcast Of February 12th Presentation At The 15th Annual BIO CEO & Investor Conference - Business Wire 02.06.13 | 05:02 pm
- Exelixis Announces COMETRIQ™ (cabozantinib) Is Now Available In The U.S. - Business Wire 01.24.13 | 11:01 am
- Exelixis Announces Webcast Of January 9 Presentation At The J.P. Morgan 31st Annual Healthcare Conference - Business Wire 12.13.12 | 04:12 pm
- Exelixis Announces EMA Acceptance Of Marketing Authorization Application For COMETRIQ™ (cabozantinib) - Business Wire 11.29.12 | 04:11 pm
- FDA Approves COMETRIQ™ (Cabozantinib) For Treatment Of Progressive, Metastatic Medullary Thyroid Cancer - Business Wire 11.29.12 | 04:11 pm
- Exelixis Announces Webcasts Of Upcoming Investor Conference Presentations In November - Business Wire 11.05.12 | 04:11 pm
Partner Headlines for EXEL
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- 5 Medical Stock Losers From Last Week With High Short Ratios - Seeking Alpha 12.22.12 | 06:12 am
- Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling - Seeking Alpha 12.02.12 | 09:12 am
- Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic Castration-Resistant Prostate Cancer - Benzinga 09.30.12 | 11:09 am
- After Hours Most Active for Sep 4, 2012 : LYB, HT, SHLD, QQQ, KGC, MTL, CVH, BAC, EXEL, MSFT, FB, FRAN - NASDAQ 09.04.12 | 08:09 pm
- UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution - Benzinga 08.20.12 | 01:08 pm
- Pre-Market Most Active for Aug 9, 2012 : EXEL, RBN, NOK, BAC, CSCO, ALLY^A, SIRI, AHL, QQQ, WIN, SPH, MNST - NASDAQ 08.09.12 | 12:08 pm
- FDA's Oncologic Drugs Advisory Committee to Review Exelixis New Drug Application for Cabozantinib November 9, 2012 - Benzinga 08.09.12 | 08:08 am
- Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC) - Benzinga 07.30.12 | 01:07 pm
- Jim Cramer Watchdog: SELL Facebook and 'Buy, Buy, Buy' these 4 HOT Stocks - Wall St. Cheat Sheet 07.18.12 | 12:07 pm
